Investing.com - NuCana reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
NuCana announced earnings per share of £-0.0017 on revenue of £0.00. Analysts polled by Investing.com anticipated EPS of £-0.0019 on revenue of £0.00.
NuCana shares are down 56.57% from the beginning of the year, still down 75.10% from its 52 week high of £7.83 set on January 13. They are under-performing the Nasdaq which is up 12.83% from the start of the year.
NuCana follows other major Healthcare sector earnings this month
NuCana's report follows an earnings missed by Eli Lilly on August 3, who reported EPS of £1.87 on revenue of £6.74B, compared to forecasts EPS of £1.89 on revenue of £6.6B.
Novo Nordisk ADR had beat expectations on August 4 with second quarter EPS of £0.8379 on revenue of £5.26B, compared to forecast for EPS of £0.7823 on revenue of £5.16B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar